Fundraising FoxSofinnova Partners — 2023 Investments
13 investments dated 2023 · listed companies and verified rows first · show all
BioCorteX develops personalized therapeutics using a microbiome knowledge graph and proprietary biology emulation platform to tailor drug treatments for diverse populations.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesLondon, GB
Co-investorsHoxton VenturesDraper Associates
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersQuan CapitalAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+3 more
Moon Surgical develops the Maestro robotic surgery system, a digital surgical robotics platform used by surgeons to perform procedures.
HealthtechMedical DevicesRoboticsParis, FR
Brice Gayet(Surgeon Founder)inAnne Osdoit(Chief Executive Officer)inEric Ermenault(Chief Commercial Officer)inAnne Renevot(Chief Financial Officer)inViola Fleig(Chief Operations Officer)inDavid Noonan(Chief Technology Officer)in
Co-investorsNVIDIACathay HealthStar51 CapitalJohnson & Johnson Innovation – JJDCNVentures
Nuage Therapeutics develops drug discovery technologies for disordered proteins, focusing on precision treatments for aggressive cancers with limited therapeutic options.
AI & Machine LearningBiotechDeep TechBarcelona, ES
Mateusz Biesaga(Founder and Chief Technology Officer)inXavier Salvatella(Founder)in
Co-investorsAsabys PartnersBStartup
Alia Therapeutics is a biotech company developing therapeutics based on gene-editing technology.
BiotechDeep TechHealthtech
Co-investorsIndaco Venture Partners
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfa+4 more
CorVent Medical develops medical ventilators, including the RESPOND ventilator, that provide ICU-standard respiratory support for acute and post-acute patients.
HardwareHealthtechMedical DevicesFargo, US
Murphy Travis(Executive Officer)inJeremy Nelson(Executive Officer)inRichard S. Walsh(Executive Officer, Director)inJohn O'Mahony(Executive Officer)inRob Faulkner(Director)Lukas Geunther(Director)
Freya Biosciences develops innovative therapies targeting immune-mediated diseases that affect women.
BiotechFemTechHealthtech
Colleen Acosta, PhD(CEO, Co-Founder)Johan van Hylckama Vlieg, PhD(CSO, Co-Founder)
Co-investorsAngelini VenturesIndaco Venture PartnersOMX VenturesBill & Melinda Gates Foundation
Julier Medical is a Paris-based, pre-clinical medical device startup developing a mechanical thrombectomy device to remove blood clots and restore blood flow in acute ischemic stroke patients.
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsAbbVie+7 more
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsCambridge Innovation CapitalF-Prime CapitalSanofi VenturesBusiness Growth FundDigitalis VenturesUniversity of Cambridge Enterprise
Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.
BiotechBrooklyn, US
Valentina Gomez(Executive Officer, Director)inTheanne Schiros(Executive Officer)Chui-lian Lee(Founder)in
BoardCorinna Chen(Director)inMichael Krel(Director)in
Co-investorsMaterial Impact
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Hotspot
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.